Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Froniglutide by ImmunoForge for Inclusion Body Myositis (IBM): Likelihood of Approval
Froniglutide is under clinical development by ImmunoForge and currently in Phase II for Inclusion Body Myositis (IBM). According to GlobalData,...
Froniglutide by ImmunoForge for Polymyositis: Likelihood of Approval
Froniglutide is under clinical development by ImmunoForge and currently in Phase II for Polymyositis. According to GlobalData, Phase II drugs...
Froniglutide by ImmunoForge for Dermatomyositis: Likelihood of Approval
Froniglutide is under clinical development by ImmunoForge and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Pemziviptadil by ImmunoForge for Congestive Heart Failure (Heart Failure): Likelihood of Approval
Pemziviptadil is under clinical development by ImmunoForge and currently in Phase I for Congestive Heart Failure (Heart Failure). According to...
Pemziviptadil by ImmunoForge for Cystic Fibrosis: Likelihood of Approval
Pemziviptadil is under clinical development by ImmunoForge and currently in Phase I for Cystic Fibrosis. According to GlobalData, Phase I...
Pemziviptadil by ImmunoForge for Cardiomyopathy: Likelihood of Approval
Pemziviptadil is under clinical development by ImmunoForge and currently in Phase I for Cardiomyopathy. According to GlobalData, Phase I drugs...